12 Facts About Vibegron


Vibegron, sold under the brand name Gemtesa, is a medication for the treatment of overactive bladder.

FactSnippet No. 626,572

Vibegron is a selective beta 3 adrenergic receptor agonist.

FactSnippet No. 626,573

Vibegron is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency in adults.

FactSnippet No. 626,574

Vibegron is a selective beta3AR agonist that is developed in Japan by Kyorin Pharmaceutical Co.

FactSnippet No. 626,575

Vibegron has been proven effective in 5 key clinical trials.

FactSnippet No. 626,576

Related searches

Japan United States

Vibegron was approved for medical use in the United States in December 2020.

FactSnippet No. 626,577

Vibegron is a selective agonist for the beta-3 adrenergic receptor.

FactSnippet No. 626,578

Vibegron was evaluated in patients with overactive bladder in several clinical studies.

FactSnippet No. 626,579

Vibegron is in contrast to other OAB drugs very selective and leads to a lesser degree in unwanted side effects.

FactSnippet No. 626,580

Vibegron is found to be a substrate for CYP3A4 in vivo, but does not actually induce or inhibit any of the cytochrome P450 enzymes and is thus less likely to take part in drug–drug interactions.

FactSnippet No. 626,581

Apart from the no to little DDIs, Vibegron has an additional safety quality in that it does not cross the blood-brain barrier and therefore does not induce cognitive impairment.

FactSnippet No. 626,582

Furthermore, Vibegron can be taken with or without food, this does not have an effect on vibegron plasma concentrations.

FactSnippet No. 626,583